Financial Gravity Companies’s Pacira BioSciences PCRX Stock Holding History

Financial Gravity Companies’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$8K	Buy	+200	New	+$9.34K	0.01%	633

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Financial Gravity Companies's PCRX Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Pacira BioSciences (PCRX) in Q4 2018: 200 shares worth $8K. The stake represents 0.01% of the portfolio and ranks #633 among its holdings.

208 funds tracked by Wall St. Rank hold PCRX as of Q4 2018.

Financial Gravity Companies held 200 shares of Pacira BioSciences worth $8K as of Q4 2018.
Pacira BioSciences was a new Financial Gravity Companies position in Q4 2018.
Pacira BioSciences made up 0.01% of Financial Gravity Companies's portfolio in Q4 2018, its #633 holding.
208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.